# Combination Therapy of SyB C-1101 and Azacytidine in Patients With Myelodysplastic Syndrome

> **NCT02783547** · PHASE1 · WITHDRAWN · sponsor: **SymBio Pharmaceuticals**

## Conditions studied

- Myelodysplastic Syndrome

## Interventions

- **DRUG:** SyB C-1101 and Azacytidine

## Key facts

- **NCT ID:** NCT02783547
- **Lead sponsor:** SymBio Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-12
- **Primary completion:** 2017-06
- **Final completion:** 2017-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The trial was withdrawn due to problems with the manufacture of the investigational drug.
- **Last updated:** 2022-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02783547

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02783547, "Combination Therapy of SyB C-1101 and Azacytidine in Patients With Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02783547. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*